|
Investigation: visual inspection: scratches on the outer housing of the valve and tissue residues were observed through the visual inspection.Permeability test: a permeability test has shown that the valve is permeable.Adjustment test: the m.Blue valve was tested and is adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.Computer controlled test: to investigate the claim of over/under-drainage, the opening pressure is measured using a miethke computer controlled testing apparatus which simulates a cerebrospinal fluid flow.The results show that the valve is operating within the accepted tolerance in the horizontal but not in the vertical position.Internal inspection: after dismantling the valve, deposits were found in m.Blue.Results: based on our investigation, we confirm that the valve shows a slower flow of liquid, likely due to the deposits observed inside the valve.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hc-therapy by shunt implants.We can exclude a defect at the time of release.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required from our point of view.
|